Effectiveness of Bacillus Calmette Guerin (BCG) vaccination in the prevention of leprosy: a population-based case-control study in Yavatmal District, India
- PMID: 15661132
- DOI: 10.1016/j.puhe.2004.04.007
Effectiveness of Bacillus Calmette Guerin (BCG) vaccination in the prevention of leprosy: a population-based case-control study in Yavatmal District, India
Abstract
Objective: To estimate the effectiveness of Bacillus Calmette Guerin (BCG) vaccination in the prevention of leprosy. Study design. Population-based case-control study.
Methods: The study was carried out in Yavatmal District, Maharashtra, India. It included 364 cases of leprosy (diagnosed by the World Health Organization's criteria), born since 1962, that were detected during a leprosy survey conducted by the Government of Maharashtra in 2,175,514 people. Each case was pair-matched with one neighbourhood control for age, sex and socio-economic status. Exclusion criteria for controls included past or current history of tuberculosis or leprosy. BCG vaccination status was assessed by examination for the presence of a BCG scar, immunization records if available and information from subjects/parents of children. Subjects who were uncertain about BCG vaccination were not included.
Results: A significant protective association between BCG and leprosy was observed [odds ratio=0.46, 95% confidence intervals (CI) 0.34-0.61]. Overall vaccine effectiveness (VE) was 54% (95% CI 39-66). BCG effectiveness against multibacillary, paucibacillary and single skin lesion leprosy was 68% (95% CI 26-86), 57% (95% CI 29-74) and 48% (95% CI 22-65), respectively. Analysis of linear trend revealed a significant linear association between the protective effect of BCG and the type of leprosy. The BCG vaccine was more effective in those aged < or =20 years compared with those aged >20 years (VE 61%, 95% CI), among females compared with males (VE 60%, 95% CI), in lower socio-economic strata compared with upper and middle strata (VE 57%, 95% CI), and in subjects who had a BCG scar size < or =5 mm compared with those with a BCG scar size >5 mm (VE 61%, 95% CI). However, these differences were not statistically significant, as reflected by the overlapping 95% CIs. The overall prevented fraction was 35% (95% CI 22-46).
Conclusion: The current study identified a beneficial role of BCG vaccination in the prevention of leprosy in the study population.
Similar articles
-
Scar size and effectiveness of Bacillus Calmette Guerin (BCG) vaccination in the prevention of tuberculosis and leprosy: a case-control study.Indian J Public Health. 2007 Jul-Sep;51(3):184-9. Indian J Public Health. 2007. PMID: 18229442
-
Effectiveness of Bacillus Calmette Guerin (BCG) vaccination in the prevention of leprosy: a population-based case-control study in Raipur, India.Indian J Public Health. 2007 Apr-Jun;51(2):86-90. Indian J Public Health. 2007. PMID: 18240467
-
Effectiveness of bacillus Calmette-Guerin (BCG) vaccination in the prevention of leprosy; a case-finding control study in Nagpur, India.Int J Lepr Other Mycobact Dis. 1998 Sep;66(3):309-15. Int J Lepr Other Mycobact Dis. 1998. PMID: 9934357
-
ILEP organisations should strive for high BCG coverage in communities at risk of leprosy.Lepr Rev. 2007 Jun;78(2):88-101. Lepr Rev. 2007. PMID: 17824479 Review.
-
[Results of the BCG vaccination in Hungary since 1929: evaluation of preventive and immunotherapeutic effectiveness].Orv Hetil. 1998 Jun 28;139(26):1563-70. Orv Hetil. 1998. PMID: 9676117 Review. Hungarian.
Cited by
-
Leprosy: a review of laboratory and therapeutic aspects--part 2.An Bras Dermatol. 2014 May-Jun;89(3):389-401. doi: 10.1590/abd1806-4841.20142460. An Bras Dermatol. 2014. PMID: 24937811 Free PMC article.
-
Factors associated with the development of leprosy in Brazilian contacts: a systematic review.Rev Inst Med Trop Sao Paulo. 2022 Sep 30;64:e55. doi: 10.1590/S1678-9946202264055. eCollection 2022. Rev Inst Med Trop Sao Paulo. 2022. PMID: 36197417 Free PMC article.
-
Advances and hurdles on the way toward a leprosy vaccine.Hum Vaccin. 2011 Nov;7(11):1172-83. doi: 10.4161/hv.7.11.16848. Epub 2011 Nov 1. Hum Vaccin. 2011. PMID: 22048122 Free PMC article. Review.
-
The immunopathobiology of syphilis: the manifestations and course of syphilis are determined by the level of delayed-type hypersensitivity.Am J Dermatopathol. 2011 Jul;33(5):433-60. doi: 10.1097/DAD.0b013e3181e8b587. Am J Dermatopathol. 2011. PMID: 21694502 Free PMC article. Review.
-
The continuing challenges of leprosy.Clin Microbiol Rev. 2006 Apr;19(2):338-81. doi: 10.1128/CMR.19.2.338-381.2006. Clin Microbiol Rev. 2006. PMID: 16614253 Free PMC article. Review.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Medical
Miscellaneous